GSK Buys Aiolos Bio for Up to $1.4 Billion
09 January 2024 - 6:39PM
Dow Jones News
By Christian Moess Laursen
GSK said it has bought Aiolos Bio, a biopharmaceutical company
focused on patients with respiratory and inflammatory conditions,
for an upfront consideration of $1.0 billion, with the potential
for an additional $400 million.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
January 09, 2024 02:24 ET (07:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2023 to Jun 2024
